- Home
- LEGH vs KROS Comparison
LEGH vs KROS Comparison
Compare LEGH & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- KROS
- Stock Information
- Founded
- LEGH 2005
- KROS 2015
- Country
- LEGH United States
- KROS United States
- Employees
- LEGH N/A
- KROS N/A
- Industry
- LEGH Homebuilding
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- KROS Health Care
- Exchange
- LEGH Nasdaq
- KROS Nasdaq
- Market Cap
- LEGH 601.1M
- KROS 589.8M
- IPO Year
- LEGH 2018
- KROS 2020
- Fundamental
- Price
- LEGH $24.49
- KROS $10.15
- Analyst Decision
- LEGH Buy
- KROS Buy
- Analyst Count
- LEGH 2
- KROS 11
- Target Price
- LEGH $29.00
- KROS $68.83
- AVG Volume (30 Days)
- LEGH 74.7K
- KROS 1.9M
- Earning Date
- LEGH 11-12-2024
- KROS 02-26-2025
- Dividend Yield
- LEGH N/A
- KROS N/A
- EPS Growth
- LEGH N/A
- KROS N/A
- EPS
- LEGH 2.18
- KROS N/A
- Revenue
- LEGH $163,718,000.00
- KROS $651,000.00
- Revenue This Year
- LEGH N/A
- KROS $303.39
- Revenue Next Year
- LEGH $8.19
- KROS N/A
- P/E Ratio
- LEGH $11.21
- KROS N/A
- Revenue Growth
- LEGH N/A
- KROS 8037.50
- 52 Week Low
- LEGH $19.42
- KROS $9.78
- 52 Week High
- LEGH $29.31
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- LEGH 49.66
- KROS 18.48
- Support Level
- LEGH $22.36
- KROS $9.78
- Resistance Level
- LEGH $24.98
- KROS $16.49
- Average True Range (ATR)
- LEGH 0.65
- KROS 0.89
- MACD
- LEGH 0.08
- KROS 0.91
- Stochastic Oscillator
- LEGH 64.24
- KROS 7.36
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to customers to facilitate the sale of homes.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.